Jobs

Passionate about building a future powered by science?
Check out the opportunities in our portfolio companies.
Powered by Getro
Showing 19 companies
CytoVale
CytoVale
12 jobs
Biotechnology
Data and Analytics
DeepTech
Health
Software
51 - 200

Cytovale is a medical diagnostics company focused on providing a more rapid and insightful way to diagnose fast-moving and immune-mediated diseases. Our FDA cleared IntelliSep test is pioneering a new way of quickly and accurately analyzing white blood cells to stratify a patient’s risk of sepsis by performing a biomechanical evaluation of white blood cells collected from a standard blood draw in under 10 minutes. Cytovale’s first market application will be for sepsis, one of the fastest-moving, most lethal conditions in the world. Sepsis, a dysregulated immune response to infection, is often difficult to quickly and accurately diagnose. Sepsis is the no. 1 cause of death in hospitals, taking the lives of 270,000 people every year in the U.S. – more than opioid overdoses, prostate cancer, and breast cancer combined. Mortality from sepsis increases as much as eight percent with every hour of delayed treatment, and as much as 80 percent of sepsis deaths could be prevented with rapid diagnosis and treatment, making early detection essential. Cytovale aims to provide critical insight for early identification of patients at risk of having sepsis, in the time needed for it to be useful.

Zymochem
Zymochem
11 jobs
Biotechnology
DeepTech
Manufacturing
11 - 50
Seed

The world they live in is built from petroleum. The paints on their walls, the carpets in their homes, the tires on their cars, the plastics for everyday consumer goods – these and many more products are made from chemicals that are mostly made from petroleum, creating a $3 trillion/yr industry. To fulfill their dependency on petroleum, they do crazy things like setting up oil rigs in the middle of the ocean and drilling several miles into the ocean floor! They’ve done these things because they have had no alternative to meet their needs. Not anymore! Over the past decade, advances in engineering microorganisms have afforded us the opportunity to make the same chemicals that are traditionally made from petroleum. Instead of requiring raw materials buried deep within the earth, microbes can use abundant and renewable sources of carbon such as sugars during processes akin to brewing beer. Despite the numerous advantages, making chemicals this way at the industrial level is still rare. This is because it’s still more expensive than using petroleum for producing the chemicals. Although a few challenges need to be solved to usher in the era of renewable chemicals, a fundamental constraint that limits the economic competitiveness of using microbes is the loss of at least 33% of the carbon as carbon dioxide waste during the fermentation – think of this as the head on your beer. Because of this carbon loss, potential product is simply not made. In technical terms, the maximum achievable yields are 67%. As sugars are the most expensive component of a bioprocess, making the carbon dioxide waste translates to as much as 20% of total costs, which severely hampers the economics of the bioprocess and its competitiveness with petroleum-based production methods. At ZymoChem, they are re-imagining the microbe, one that is designed to eliminate (or substantially reduce) carbon loss during the production of chemicals. To do this, they had to design a completely new biosynthetic pathway – one that doesn’t exist in nature – to make the chemicals. Each individual step of this pathway is designed to not lose carbon as carbon dioxide, enabling their biosynthetic pathway to retain all of the sugar’s carbon into the final chemical product. This carbon conservation allows their approach to have superior theoretical yields, up to 50% better than existing state-of-the-art technology! In turn, their technology has the potential to substantially lower production costs and drastically improve cost-competitiveness for making a variety of chemicals from renewable sources, even at today's oil prices.

Biotechnology
DeepTech
Design
Health
11 - 50
Series A

A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.

Biotechnology
DeepTech
Manufacturing
Professional Services
Sustainability
51 - 200
Series C+

Ecovative uses biology to solve fundamental human needs at industrial scales and in consumer applications. Ecovative uses mycelium to grow category defining products ranging from leather like textiles to sustainable packaging to high performance foams for apparel and beauty. Ecovative has been widely recognized for its technical and environmental contributions by organizations like the World Economic Forum and in the media including Wired Magazine, Forbes, and Time.

Biotechnology
DeepTech
51 - 200
Series C+

Modern Meadow is a purpose-driven company positioned at the intersection of material science and biology with a mission to be a catalyst for real-world impact on people and the planet. Modern Meadow’s proprietary Bio-Alloy™ and Bio-F@rm™ technology application platforms harness the unique properties of tuned proteins to sustainably move the world away from petrochemical and animal-derived inputs without compromising on performance. These innovations can drop into any existing infrastructures for immediate scalable adoption in the materials, beauty, and other industries. Our close relationship with development partners and production facilities allows companies partnering with Modern Meadow to feel confident knowing our products are 100% traceable from Lab-to-Brand™.

Biotechnology
Data and Analytics
DeepTech
Health
Software
1 - 10

CellChorus provides a comprehensive, dynamic analysis of single cells for biopharmaceutical companies. The company’s TIMING™ platform applies visual AI to evaluate cell activation, killing and movement as a function of time in order to maximize our understanding of the cellular function, state, and phenotype of immuno-oncology and other therapies.

Biotechnology
DeepTech
Health
1 - 10
Seed

Parallel Bio develops tools that help in the discovery and development of immunotherapies, to eliminate current barriers and create the fastest path to a drug that works. Parallel Bio's platform combines best-in-class human immune organoids with computational methods to generate unprecedented insights into human health and disease.

Biotechnology
DeepTech
Health
11 - 50
Seed

EnPlusOne is on a mission to bring RNA and RNA solutions to the world. Its ezRNA synthesis platform is a stepwise innovation that can incorporate a diverse array of nucleotide modifications and promises a manufacturing process that can sustainably deliver therapeutic RNA at commercial scales. In addition to direct RNA synthesis, EnPlusOne's ezRNA platform supports a vast array of RNA solution applications. For more information, please visit www.enplusonebio.com

Biotechnology
Data and Analytics
DeepTech
Software
1 - 10
Seed

Canaery is a neurotechnology and SaaS data company on a mission to introduce the world’s first enhanced working animals and unlock the hidden world of scent. By building a networked database of detectable odors, Canaery can revolutionize border and transportation security, medical screening and health diagnostics, and invasive pest inspections to make a safer, healthier society.

Biotechnology
DeepTech
11 - 50
Seed

Noetik is an AI-native biotechnology company. By harnessing the potential of self-supervised learning and human multimodal data, Noetik aims to discover better precision immunotherapies.

Biotechnology
DeepTech
Health
1 - 10
Seed

Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas.

Biotechnology
DeepTech
Health
11 - 50
Seed

Phantom Neuro creates a system that will enable lifelike control of robotic orthopedic technologies, such as prosthetic limbs and exoskeletons.